Search published articles


Showing 6 results for Jam Ashkezari

Nasibe Zolfaghari, Mohammad Faramarzi, Mohammad Afkhami-Ardekani, Arezoo Afkhami-Ardekani, Saeedah Jam Ashkezari,
Volume 7, Issue 2 (volume 7, number2 2015)
Abstract


Arezoo Afkhami-Ardekani, Mahmood Reza Motamedzadeh, Saeedeh Jam Ashkezari, Mohammad Afkhami-Ardekani,
Volume 7, Issue 3 (volume 7, number3 2015)
Abstract

Objective: The aim of this study was to evaluate the effect of zinc and magnesium supplementation on glycemic control and serum insulin in type 2 diabetic patients.

Materials and Methods: In this randomized clinical trial 70 diabetic patients who referred to Yazd Diabetes Center were selected. Subjects received 500 mg/day magnesium oxide or 100 mg/day zinc sulfate randomly for 8 weeks. At the start and end of treatment period fasting blood sugar (FBS), 2 hour postprandial glucose (2-hpp), glycated hemoglobin (HbA1C) and fasting insulin level were measured.

Results: Magnesium and Zinc supplementation for 8 weeks cause significantly decrease in HbA1c (P=0.005, P=0.001).No significantly difference was observed after trial between magnesium and zinc groups in FBS (42.08 ±7.43 vs. 35.15 ± 6.52) (P=0.97), HbA1C (1.22±0.21 vs. 1.77±0.32) (P=0.07) and fasting serum insulin (39.81 ±7.03 vs.36.68±6.81) (P=0.83) respectively.

Conclusion: Results of this study showed that 500 mg/day magnesium oxide or 100 mg/day zinc sulfate administration for 8 weeks could improve HbA1C in type 2 diabetic patients and this effect is same in two groups. But more studies for evaluating effect of magnesium and zinc supplementation on type 2 diabetic patients were suggested.


Masoud Reza Manaviat, Mansour Rafiee, Fariba Sepehri, Narjes Hazar, Ahmad Shojaaldini, Saeedeh Jam Ashkezari, Masoud Rahmanian,
Volume 10, Issue 4 (volume 10, number 4 2018)
Abstract

Objective: Remote Ischemic Preconditioning (RIPC) as the transient ischemia and reperfusion of the arm is a promising method for protecting different tissue from future ischemia. These effects might be mediated through vascular and endothelial growth factor (VEGF) pathway. We investigated the influence of RIPC on diabetic macular edema (DME) as a chronic ischemic condition in patients who were candidate to receive anti-VEGF therapy.
Materials and Methods: In this Single blinded, randomized controlled trial, 40 eligible type 2 diabetes mellitus (T2DM) patients with macular edema who were candidate to receive anti-VEGF therapy randomized into intervention (CP) and sham controlling (SP). The CP received RIPC in three consecutive days before anti-VEGF injection. Data of optical cochrane tomography (OPC) before and 10 days after procedure were compared as outcomes.
Results: Central foveal volume and visual acuity mean difference before and after intra-vitral anti-VEGF injection in both groups was significant. There were no significant mean differences in central macular thickness in case groups. Comparing the mean between two groups did not show a significant difference in visual acuity, central foveal volume (P-value: 0.69) and central macular thickness (P-value: 0.62). There were no significant differences in the desired changes pattern of DME between two groups (P-value: 1.00).
Conclusion: This pilot study did not show any additive positive effect of RIPC on retinal outcomes especially visual acuity in T2DM patients with DME who were received anti-VEGF treatment.

 
Marzieh Aboutorabi-Zarchi, Saeedeh Jam Ashkezari, Somaye Gholami, Seid Kazem Razavi-Ratki, Nasim Namiranian,
Volume 11, Issue 1 (volume 11, number 1 2019)
Abstract

Objective: The relative stroke risk is increased in patients with diabetes. Awareness and knowledge of the risk factors and symptoms of stroke are essential for prevention and immediate effective treatment of stroke. The aim of the study was to determine baseline knowledge about the warning symptoms and risk factors of stroke in patients with type 2 diabetes (T2DM).
Materials and Methods: This analytical cross-sectional study was conducted in Yazd-Iran 2015-2016. The pilot section included 10 T2DM patients. The main data was collected from 281 patients. The self-conducted checklist about knowledge of stroke risk factors, warning signs as defined by national institute of neurological disorder and stroke was prepared in three following parts. 1) Socio-demographic information. 2) Open-ended question about stroke risk factors, warning sign & symptoms and first action information. 3) Multiple choice questions related to the stroke risk factors, warning sign & symptoms and first action information.
Results: 408 T2DM patients were invited and 281 patients fulfilled in study. Most of them (70.4%) were women. The mean age of patients was 54.09±12.54 years. The most common general risk factors of stroke listed were “high blood pressure (92.9%), unhealthy diet” (86.8%), and “stress” (82.2%).The most common sources of stroke information were friends and family members (73.7%).
Conclusion: Education program to increase T2DM knowledge of stroke may contribute to reducing the risk of stroke and increasing the speed of hospital presentation after the onset of stroke.

 
Marzieh Aboutorabi-Zarchi, Saeedeh Jam Ashkezari, Somaye Gholami, Seid Kazem Razavi-Ratki, Nasim Namiranian,
Volume 11, Issue 1 (volume 11, number 1 2019)
Abstract

Objective: The relative stroke risk is increased in patients with diabetes. Awareness and knowledge of the risk factors and symptoms of stroke are essential for prevention and immediate effective treatment of stroke. The aim of the study was to determine baseline knowledge about the warning symptoms and risk factors of stroke in patients with type 2 diabetes (T2DM).
Materials and Methods: This analytical cross-sectional study was conducted in Yazd-Iran 2015-2016. The pilot section included 10 T2DM patients. The main data was collected from 281 patients. The self-conducted checklist about knowledge of stroke risk factors, warning signs as defined by national institute of neurological disorder and stroke was prepared in three following parts. 1) Socio-demographic information. 2) Open-ended question about stroke risk factors, warning sign & symptoms and first action information. 3) Multiple choice questions related to the stroke risk factors, warning sign & symptoms and first action information.
Results: 408 T2DM patients were invited and 281 patients fulfilled in study. Most of them (70.4%) were women. The mean age of patients was 54.09±12.54 years. The most common general risk factors of stroke listed were “high blood pressure (92.9%), unhealthy diet” (86.8%), and “stress” (82.2%).The most common sources of stroke information were friends and family members (73.7%).
Conclusion: Education program to increase T2DM knowledge of stroke may contribute to reducing the risk of stroke and increasing the speed of hospital presentation after the onset of stroke.
Reyhaneh Azizi, Nasim Namiranian, Saeedeh Jam Ashkezari, Miaad Hassani Kaboutarkhani, Somaye Gholami, Zahra Davoudi, Fatemeh Aghaei Meybodi,
Volume 11, Issue 4 (volume 11, number4 2019)
Abstract

Objective: Pioglitazone is one of the oral medications of type 2 diabetes (T2DM). The purpose of this study was to evaluate the effect of pioglitazone on asthma and diabetes treatment outcomes among patients with concurrent asthma and T2DM.
Materials and Methods: We conducted a quasi-experimental study on 11 patients with concurrent asthma and T2DM in Yazd Afshar Hospital and Yazd diabetic research center 2014-2017. The inclusion criteria were patients between 20-60 years old, at least one year with concurrent asthma and T2DM (documented with spirometer, bronchodilator test), ejection fraction more than 50%. Patients who were smoker, on oral corticosteroids, phenobarbital, methotrexate, rifampin, phenytoin and gemfibrozil were excluded. Laboratory tests (FBS, HbA1c, 2hpp, leptin), spirometer test, exhaled nitric oxide were done before and after 10 weeks of pioglitazone medication. All patients were visited every two weeks. The before and after pioglitazone treatment differences were checked by paired t-test and Wilcoxon Rank sum test.
Results: The mean (± SD) age of participants was 55.81 (±7.66). The median of differences of leptin (p-value: 0.885), FEV1 to FVC (P-value: 0.185), FEV1 (p-value: 0.386), NO (P-value: 0.574), FVC percent (P-value: 0.477), FEV1 percent (P-value: 0.515) did not differ before and after pioglitazone treatment.   
Conclusion: Our finding suggested that pioglitazone may not be effective in the treatment and improvement of respiratory function in T2DM with concurrent asthma. 

Page 1 from 1     

© 2023 CC BY-NC 4.0 | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb